Technical Analysis for CDTX - Cidara Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 1.9 -4.04% -0.08
CDTX closed down 4.04 percent on Friday, September 20, 2019, on 44 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Down
See historical CDTX trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Stochastic Reached Oversold Weakness 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup -4.04%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -4.04%
MACD Bearish Signal Line Cross Bearish -4.04%
1,2,3 Pullback Bullish Bullish Swing Setup -4.04%

Older signals for CDTX ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Cidara Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases. Its lead product candidate is CD101 IV, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of systemic Candida infections. The company also develops CD101 topical, a topical formulation of CD101 for the treatment of recurrent vulvovaginal candidiasis, a prevalent mucosal infection. In addition, it develops a proprietary immunotherapy technology platform, Cloudbreak, which is used to create compounds designed to direct a patient's immune cells to attack and eliminate pathogens that cause infectious disease. Cidara Therapeutics is developing its first Cloudbreak development candidate, C001, for the treatment of invasive aspergillosis; and evaluating additional opportunities to expand its Cloudbreak immunotherapy platform to other areas of infectious disease. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in June 2014. Cidara Therapeutics, Inc. was founded in 2012 and is based in San Diego, California.
Biopharmaceutical Medical Specialties Diseases Infectious Diseases Immunotherapy Infectious Disease Anti Infectives Immunotherapy Technology
Is CDTX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 2 bearish and 0 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 4.95
52 Week Low 1.2225
Average Volume 552,811
200-Day Moving Average 2.2149
50-Day Moving Average 1.6566
20-Day Moving Average 1.934
10-Day Moving Average 2.057
Average True Range 0.1735
ADX 37.68
+DI 29.8431
-DI 17.737
Chandelier Exit (Long, 3 ATRs ) 2.5695
Chandelier Exit (Short, 3 ATRs ) 1.8405
Upper Bollinger Band 2.5036
Lower Bollinger Band 1.3644
Percent B (%b) 0.47
BandWidth 58.903826
MACD Line 0.1212
MACD Signal Line 0.1474
MACD Histogram -0.0262
Fundamentals Value
Market Cap 32.04 Million
Num Shares 16.9 Million
EPS -3.55
Price-to-Earnings (P/E) Ratio -0.54
Price-to-Sales 0.00
Price-to-Book 2.16
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.09
Resistance 3 (R3) 2.11 2.07 2.06
Resistance 2 (R2) 2.07 2.02 2.06 2.05
Resistance 1 (R1) 1.98 1.99 1.96 1.96 2.04
Pivot Point 1.94 1.94 1.93 1.93 1.94
Support 1 (S1) 1.86 1.89 1.84 1.84 1.76
Support 2 (S2) 1.82 1.86 1.81 1.75
Support 3 (S3) 1.73 1.82 1.74
Support 4 (S4) 1.71